iLoF utilizes a cloud-based platform that employs photonics and AI to create a digital library of optical fingerprints for non-invasive patient screening and stratification in clinical trials. This technology reduces screening time by 70% and costs by 40%, while providing a more qualified pool of candidates for drug development.
Funding
$7.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HVFounders
Product
Problem
Current clinical trial screening methods are time-consuming, expensive, and often yield heterogeneous patient populations due to variations in disease stage and underlying pathophysiology. This can lead to increased costs and potentially flawed outcomes in drug development.
Solution
iLoF offers a cloud-based platform that uses photonics and artificial intelligence to create a digital library of optical fingerprints from patient blood samples. This non-invasive approach enables rapid patient screening and stratification for clinical trials, reducing screening time and costs. The platform identifies more qualified candidates by accounting for individual variations, leading to improved trial outcomes and more effective drug development.
Target Audience
The primary target audience includes pharmaceutical companies, clinical research organizations, and researchers involved in drug development and clinical trials, particularly those focused on Alzheimer's disease, COVID-19, and ovarian cancer.
Features
- Cloud-based platform for secure data storage and analysis
- Photonics-based technology for generating optical fingerprints from microliter blood samples
- AI-powered algorithms for patient stratification and biomarker discovery
- Non-invasive blood-based screening process
- Label-free flexibility on targets
- Rapid screening process (less than 10 seconds)
- Minimally invasive (microliters of blood required)